Samsung Biologics
₩1,351,000.00Change from previous close: −4.82%Absolute change: −₩68,363.63
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- ₩62.89T
- Enterprise value
- ₩65.1T
- Forward P/E
- 27.5
- PEG
- 1.77
- Price/sales
- 12.3
- EV/EBITDA
- 23.0
- EV/revenue
- 12.7
Profitability and growth
- Gross margin
- 54.2%
- Operating margin
- 44.4%
- Net margin
- 38.7%
- ROE
- 18.5%
- ROA
- 9.6%
- Revenue growth (year over year)
- 30.2%
- Earnings growth (year over year)
- 32.9%
Financial health
- Total cash
- ₩2.21T
- Total debt
- ₩1.24T
- Debt/equity
- 0.15
- Current ratio
- 1.80
- Quick ratio
- 0.95
Dividends
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- ₩1,971,805.40
- Median price target
- ₩1,997,168.00
- High price target
- ₩2,200,000.00
- Low price target
- ₩1,600,000.00
- Analysts with a price target
- 26
- Consensus
- Strong buy
- EPS estimate, current year
- ₩41,148.33
Shares and trading
- Beta
- 0.21
- Average volume
- 51.87K
- Shares outstanding
- 46.55M
- Float
- 11.81M
- Institutional ownership
- 16.2%
- Insider ownership
- 74.4%